Cibele L Garzillo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1773831/publications.pdf

Version: 2024-02-01

36 papers	670 citations	623734 14 h-index	580821 25 g-index
46 all docs	46 docs citations	46 times ranked	1197 citing authors

#	Article	IF	Citations
1	Intensive care management of patients with COVID-19: a practical approach. Annals of Intensive Care, 2021, 11, 36.	4.6	73
2	Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study. Journal of Cardiothoracic Surgery, 2021, 16, 248.	1.1	1
3	Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. Nephrology Dialysis Transplantation, 2020, 35, 1369-1376.	0.7	13
4	Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Diseaseâ€"Reply. JAMA Internal Medicine, 2020, 180, 166.	5.1	0
5	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. JAMA Network Open, 2020, 3, e1919666.	5.9	14
6	Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF). Trials, 2020, 21, 337.	1.6	2
7	Occurrence of recently diagnosed atrial fibrillation in the immediate postoperative period of myocardial revascularization surgery. Although common, a devalued complication. Revista Da AssociaÂ§Ã£o MÃ©dica Brasileira, 2020, 66, 1473-1475.	0.7	0
8	Association Between Stress Testingâ€"Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease. JAMA Internal Medicine, 2019, 179, 1345.	5.1	24
9	VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS. Journal of the American College of Cardiology, 2019, 73, 137.	2.8	0
10	Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease. Coronary Artery Disease, 2019, 30, 536-541.	0.7	0
11	Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III. Angiology, 2019, 70, 337-344.	1.8	11
12	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. International Journal of Cardiology, 2018, 273, 63-68.	1.7	5
13	Biomarker release after percutaneous coronary intervention in patients without established myocardial infarction as assessed by cardiac magnetic resonance with late gadolinium enhancement. Catheterization and Cardiovascular Interventions, 2017, 90, 87-93.	1.7	5
14	HIGH NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS PREDICT ENHANCED PERIPROCEDURAL INFLAMMATORY RESPONSE FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN STABLE ISCHEMIC HEART DISEASE PATIENTS. Journal of the American College of Cardiology, 2017, 69, 124.	2.8	0
15	COST-EFFECTIVENESS ANALYSIS AND QUALITY OF LIFE OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTING: MASS III TRIAL 5-YEAR FOLLOW-UP. Journal of the American College of Cardiology, 2017, 69, 100.	2.8	0
16	Significant elevation of biomarkers of myocardial necrosis after coronary artery bypass grafting without myocardial infarction established assessed by cardiac magnetic resonance. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1	4
17	Abnormal elevation of myocardial necrosis biomarkers after coronary artery bypass grafting without established myocardial infarction assessed by cardiac magnetic resonance. Journal of Cardiothoracic Surgery, 2017, 12, 122.	1.1	4
18	Myocardial injury in diabetic patients with multivessel coronary artery disease after revascularization interventions. Diabetology and Metabolic Syndrome, 2017, 9, 92.	2.7	5

#	Article	IF	Citations
19	Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment. Annals of Thoracic Surgery, 2016, 101, 1735-1744.	1.3	16
20	Accuracy of Myocardial Biomarkers in the Diagnosis of Myocardial Infarction After Revascularization as Assessed by Cardiac Resonance: The Medicine, Angioplasty, Surgery Study V (MASS-V) Trial. Annals of Thoracic Surgery, 2016, 101, 2202-2208.	1.3	20
21	Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients. Cardiovascular Diabetology, 2015, 14, 66.	6.8	17
22	Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. American Heart Journal, 2013, 166, 250-257.	2.7	54
23	Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: Effect of age in the Medicine, Angioplasty, or Surgery Study II trial. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1105-1112.	0.8	12
24	Hypotheses, rationale, design, and methods for evaluation of ischemic preconditioning assessed by sequential exercise tests in diabetic and non-diabetic patients with stable coronary artery disease â€“ a prospective study. BMC Cardiovascular Disorders, 2013, 13, 117.	1.7	4
25	Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. European Heart Journal, 2013, 34, 3370-3377.	2.2	16
26	Effect of Hypoglycemic Agents on Ischemic Preconditioning in Patients With Type 2 Diabetes and Symptomatic Coronary Artery Disease. Diabetes Care, 2013, 36, 1654-1659.	8.6	29
27	Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease. Circulation, 2012, 126, S145-50.	1.6	33
28	Cancer-related deaths among different treatment options in chronic coronary artery disease. Coronary Artery Disease, 2012, 23, 79-84.	0.7	24
29	Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease. Circulation, 2012, 126, S158-63.	1.6	56
30	Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial. BMC Cardiovascular Disorders, 2012, 12, 65.	1.7	10
31	Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial. BMC Cardiovascular Disorders, 2010, 10, 47.	1.7	0
32	Five-Year Follow-Up of a Randomized Comparison Between Off-Pump and On-Pump Stable Multivessel Coronary Artery Bypass Grafting. The MASS III Trial. Circulation, 2010, 122, S48-S52.	1.6	105
33	Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 1443-1449.	0.8	21
34	Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coronary Artery Disease, 2008, 19, 383-388.	0.7	12
35	Custos comparativos entre a revascularizaÃ§Ã£o miocÃ¡rdica com e sem circulaÃ§Ã£o extracorpÃ³rea. Arquivos Brasileiros De Cardiologia, 2008, 91, 369-376.	0.8	11
36	Characterization of Reactive Astrocytes in the Chronic Phase of the Pilocarpine Model of Epilepsy. Epilepsia, 2002, 43, 107-109.	5.1	57